Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial
In this prospective, multicentre clinical trial, we evaluated zanubrutinib combined with lenalidomide, temozolomide and rituximab monoclonal antibody ± methotrexate (RLZT ± MTX) as first-line treatment for primary central nervous system lymphoma. RLZT ± MTX demonstrated good efficacy and safety, especially for elderly patients who cannot undergo intensive chemotherapy.
Authors
- Zongjiu Jiao
- Yihao Wang (ORCID: https://orcid.org/0000-0002-6185-3483)
- Jia Song (ORCID: https://orcid.org/0000-0002-7211-8492)
- Zhaoyun Liu (ORCID: https://orcid.org/0000-0003-2966-3564)
- D. Gao
- Yue Ren (ORCID: https://orcid.org/0009-0004-7449-5410)
- Kai Ding (ORCID: https://orcid.org/0000-0003-0160-4650)
- Jie Zhuo
- Rong Fu
- Guokai Wang
- Shan Gao
- Bing Li
- Hui Liu
Institutions
- Hebei Medical University (CN)
- Tianjin Chengjian University (CN)
- Tianjin Medical University General Hospital (CN)
- Tianjin Huanhu Hospital (CN)
- Xingtai People's Hospital (CN)
- Inner Mongolia Medical University (CN)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1111/bjh.70335
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tianjin Municipal Health Commission
- Tianjin Science and Technology Program